Cargando…
Dual immunological and proliferative regulation of immune checkpoint FGL1 in lung adenocarcinoma: The pivotal role of the YY1–FGL1–MYH9 axis
RATIONAL: Lung cancer is the most common tumor worldwide, with the highest mortality rate and second highest incidence. Immunotherapy is one of the most important treatments for lung adenocarcinoma (LUAD); however, it has relatively low response rate and high incidence of adverse events. Herein, we...
Autores principales: | Tang, Xi-Yang, Xiong, Yan-Lu, Zhao, Ya-Bo, Yang, Jie, Shi, An-Ping, Zheng, Kai-Fu, Liu, Yu-Jian, Shu, Chen, Jiang, Tao, Ma, Nan, Zhao, Jin-Bo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9577086/ https://www.ncbi.nlm.nih.gov/pubmed/36268014 http://dx.doi.org/10.3389/fimmu.2022.1014053 |
Ejemplares similares
-
Immune Checkpoint LAG3 and Its Ligand FGL1 in Cancer
por: Shi, An-Ping, et al.
Publicado: (2022) -
Fibrinogen-like protein 1 (FGL1): the next immune checkpoint target
por: Qian, Wenjing, et al.
Publicado: (2021) -
Immune Checkpoint FGL1 Expression of Circulating Tumor Cells Is Associated With Poor Survival in Curatively Resected Hepatocellular Carcinoma
por: Yan, Qing, et al.
Publicado: (2022) -
FGL2 is positively correlated with enhanced antitumor responses mediated by T cells in lung adenocarcinoma
por: Yuan, Kai, et al.
Publicado: (2020) -
Fgl2: link between hepatitis B and SARS?
por: Robertson, Morag
Publicado: (2003)